Brooks Laboratories Limited
BROOKS · NSE · Healthcare
StocksWizard rates Brooks Laboratories Limited a Buy, scoring 61/100 on our blended model. At ₹66.68 it trades below our blended DCF and relative-multiples fair value of ₹133.36, implying roughly 100% upside to that estimate — we read the stock as undervalued by 100%. Financial health scores 97/100 (grade A), in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 9 of 12 investability checks, with durability 76, valuation 100 and momentum 41 on our 0–100 scales.
These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹106.69. Low-confidence estimate — limited data.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%22.3%
- ✓Low debt (D/E < 0.5)0.07x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-13%
- –Earnings growing
- ✓Net margin ≥ 10%28.7%
- ✓Current ratio > 1.51.72
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.86
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-19Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (22.3%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (28.7%).
- •Financially solid — Altman Z 4.86.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Well off its 52-week high — possible mean-reversion.
- •Trades ~100% below our estimated fair value.
About Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controll
More in Healthcare
All stocksOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.